QIAGEN integrates quality control tools into GeneReader NGS System
May 31 2016

QIAGEN integrates quality control tools into GeneReader NGS System

Reference data set from Horizon affirms proven accuracy of GeneReader workflow

Hilden, Germany, and Germantown, Maryland, May 31, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group’s industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight. 

In addition, QIAGEN’s GeneRead QIAact Actionable Insights Tumor Panel, the first in a family of multiplex panels for the GeneReader NGS System, has demonstrated the highest levels of accuracy, consistency and reliability in extensive testing compared with Horizon’s control data. The workflow achieved full concordance with the Horizon Quantitative Multiplex FFPE Reference Standards in correctly identifying eight critical cancer-linked variants above 5% allelic frequency covered by the control data. The QIAact panel targets 12 clinically actionable genes often analyzed in the most prevalent types of cancer research, including breast, ovarian, colorectal, lung and melanoma.

“We created the GeneReader NGS System to provide the world’s first truly complete solution for next-generation sequencing, everything a research laboratory needs to achieve actionable insights, and now QIAGEN is the only company to offer quality control for complete NGS workflows. Labs can effectively manage NGS with one vendor from Sample to Insight, rather than juggling the complexity of many providers,” said Jonathan Arnold, QIAGEN’s Oncology Franchise Business Leader. “Integrating Horizon controls into the GeneReader NGS System workflow makes quality assurance easier for users, from system set-up and training laboratory staff to guiding workflow quality control. QIAGEN scientists have proven our Actionable Insights Tumor Panel as robust and reliable based on Horizon data, confirming earlier findings by the respected Broad Institute.” 

Dr. Yassmine Akkari, Molecular Pathology Technical Director for Legacy Health in Portland, Oregon, said: “As a laboratory director, my responsibility is to deliver accurate results in a timely manner. Reference standards and protocols are critical to labs like mine to establish confidence in a testing platform, and to use in important training and QC processes. This dataset published by QIAGEN is the first of its kind for NGS, and the comparison of the Actionable Insights Tumor Panel to Horizon’s industry benchmarks affirms the accuracy and reliability of the GeneReader NGS system.”

“We are pleased that QIAGEN has chosen Horizon as a partner”, said Dr. Paul Morrill, President, Products Business, Horizon Discovery Group. “The incorporation of our widely-used and well-established reference standards as a data set into the GeneReader NGS workflow demonstrates the quality of the system and underlines the critical role our reference samples play in the adoption of NGS workflows by clinical research laboratories.”

The GeneReader NGS System, introduced in late 2015, is gaining rapidly worldwide adoption as a highly efficient solution to address fragmented NGS workflows and bottlenecks that have hindered many research labs from achieving actionable insights from next-generation sequencing. QIAGEN is developing a range of enhancements that will add further value, including upcoming gene panels with additional content focusing on breast and lung cancer.

QIAGEN will demonstrate the GeneReader NGS System together with its other Sample to Insights solutions for molecular diagnostic and research applications in oncology at Booth 18031 at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting on June 3-7, 2016, in Chicago. For more information on QIAGEN’s presence at ASCO please visit oncologysolutions.qiagen.com/asco.



QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Share this page